Cassava Sciences shares dropped after the company agreed to a $40 million settlement with the Securities and Exchange ...

Alzheimer’s drug developer Cassava Sciences Inc (NASDAQ:SAVA), its founder Remi Barbier, and former Senior VP of Neuroscience ...

Shares of Cassava Sciences fell 10% in post-market trading on Thursday after the U.S. Securities and Exchange Commission ...

Shares of Cassava Sciences Inc. dropped more than 10% in the extended session Thursday after announcing a settlement with U.S ...

The U.S. Securities and Exchange Commission said on Thursday that it charged Cassava Sciences and two of the company's former ...

The Securities and Exchange Commission today announced Cassava Sciences, Inc., its founder and former CEO, Remi Barbier, and ...

Cassava, without admitting or denying the SEC’s allegations, agreed to pay a monetary penalty of $40 million. The Company cooperated fully with the SEC’s investigation and has implemented remedial ...

Cassava Sciences has agreed to pay $40 million to resolve an investigation into claims it made m | Cassava Sciences has ...

Cassava and former executives were charged Thursday by the SEC with making misleading claims in 2020 about trials for the ...

Cassava Sciences settles SEC charges for $40M over misleading Alzheimer's drug trial results, ex-CEO and SVP also face negligence charges.

The U.S. Securities and Exchange Commission announced Cassava Sciences Inc. (SAVA), its founder and former CEO, Remi Barbier, and its ...

Despite the settlement, the Securities and Exchange Commission on Thursday sued Cassava Sciences in the Western District ...